The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: Demonstration of a ceiling effect
- 10 May 2005
- journal article
- clinical trial
- Published by Elsevier in Vascular Pharmacology
- Vol. 43 (1) , 36-39
- https://doi.org/10.1016/j.vph.2005.03.003
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Sitaxsentan Therapy for Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Inhaled Iloprost for Severe Pulmonary HypertensionNew England Journal of Medicine, 2002
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Reference Equations for the Six-Minute Walk in Healthy AdultsAmerican Journal of Respiratory and Critical Care Medicine, 1998
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease.BMJ, 1978
- A means of assessing maximal oxygen intake. Correlation between field and treadmill testingJAMA, 1968